GHRP-6 dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of GHRP-6 actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
GHRP-6 reconstitution chart
Units on a standard U-100 insulin syringe, where 100 units is 1 mL. The rows are the absolute doses quoted in studies of GHRP-6, from 400 mcg to 5 mg, so this chart is specific to this compound rather than a generic ladder. More diluent means more units for the same dose, which is easier to measure accurately and empties the vial no faster.
| Dose | 1 mL diluent (2,000 mcg/mL) | 2 mL diluent (1,000 mcg/mL) | 3 mL diluent (667 mcg/mL) |
|---|---|---|---|
| 400 mcg | 20 | 40 | 60 |
| 5 mg | 250 >1 mL | 500 >1 mL | 750 >1 mL |
| Dose | 1 mL diluent (5,000 mcg/mL) | 2 mL diluent (2,500 mcg/mL) | 3 mL diluent (1,667 mcg/mL) |
|---|---|---|---|
| 400 mcg | 8 | 16 | 24 |
| 5 mg | 100 | 200 >1 mL | 300 >1 mL |
| Dose | 1 mL diluent (10,000 mcg/mL) | 2 mL diluent (5,000 mcg/mL) | 3 mL diluent (3,333 mcg/mL) |
|---|---|---|---|
| 400 mcg | 4 | 8 | 12 |
| 5 mg | 50 | 100 | 150 >1 mL |
Read a figure off this chart only if it matches the vial in front of you. A vial labelled a different strength, or reconstituted with a different volume, gives a different number for the same dose, and that is the single most common way these calculations go wrong.
Doses in published studies of GHRP-6
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. 8 of 10 come from human studies; the rest are animal or laboratory work.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Human clinical trial | The diagnostic test gives GHRH 1 microgram per kilogram plus GHRP-6 1 microgram per kilogram intravenously, validated in 125 patients with pituitary disease and 125 healthy controls. | pmid-11030292 |
| Human clinical trial | In a sleep study, healthy young men received 300 micrograms per kilogram orally in enteric-coated capsules, or 30 micrograms per kilogram intranasally or sublingually. | pmid-10336729 |
| Human clinical trial | Intravenous GHRP-6 at 1 microgram per kilogram was compared with GHRH 100 micrograms and their combination in 16 healthy adults. | pmid-10583306 |
| Human clinical trial | GHRP-6 90 micrograms or GHRH 100 micrograms, alone or combined, as an intravenous bolus in young and older adults. | pmid-7734029 |
| Human clinical trial | GHRH plus GHRP-6, 100 micrograms each, intravenously in 12 men with type 2 diabetes under glucose clamps. | pmid-14693411 |
| Human clinical trial | Children with short stature received 300 micrograms per kilogram orally. | pmid-7581965 |
| Human clinical trial | Nine healthy men received single intravenous boluses of 100, 200 and 400 micrograms per kilogram for pharmacokinetics. | pmid-23099431 |
| Human clinical trial | In the Cuban stroke trial, 95 patients received intravenous EGF 75 micrograms plus GHRP-6 5 mg twice daily for seven days. | pmid-42462342 |
| Animal, preclinical | Animal study, mice, 2025: doses stated in the abstract: 5 mg/kg. Only GHRP-6 (5 mg/kg) increased food intake without adverse effects, prompting detailed analysis of meal patterns, neuronal activation in the arcuate nucleus (via Fos mapping) and neurochemical identification of c-fos messenger RNA (mRNA)-expressing neurons using RNAscope. | pmid-39813130 |
| Animal, preclinical | Animal study, rats, rabbits, 2016: doses stated in the abstract: 400 μg. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL. | pmid-27200188 |
Weight-normalised doses, and why they are not on the chart
Some studies state a dose per kilogram. Those figures are deliberately absent from the chart above, because multiplying one by a body weight produces a number that looks like a dose and is not one. Interspecies scaling is not arithmetic: a rat milligram-per-kilogram figure does not become a human dose by multiplication.
- 1 microgram per kilogram intravenous, the diagnostic-test dose. pmid-11030292
- 100 to 400 micrograms per kilogram intravenous in the pharmacokinetic study; 300 micrograms per kilogram oral and 30 intranasal in the sleep study. pmid-23099431
- Animal study, mice, 2025: weight-normalized doses as published: 5 mg/kg. Only GHRP-6 (5 mg/kg) increased food intake without adverse effects, prompting detailed analysis of meal patterns, neuronal activation in the arcuate nucleus (via Fos mapping) and neurochemical identification of c-fos messenger RNA (mRNA)-expressing neurons using… pmid-39813130
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of GHRP-6 actually ran for.
- Randomized controlled trial, humans, n=95, 2026: durations stated: 7 days; 3 years; 6 months. Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93). pmid-42462342
- Randomized controlled trial, humans, 2010: durations stated: 6 months. Design/patients Eight untreated patients with CD (BMI: 28.5 +/- 0.8 kg/m(2)) were evaluated before and after 3 and 6 months of ketoconazole treatment and compared with 11 controls (BMI: 25.0 +/- 0.8). pmid-19453623
- Animal study, rats, 2026: durations stated: 7 days. Treatments were initiated post-surgery and continued for 7 days. pmid-41901314
- Animal study, rats, rabbits, 2016: durations stated: 5 days; 30 days. Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days. pmid-27200188
Storage and stability, as published
Reconstitution starts a clock. These are the storage and stability conditions stated in papers in this ledger. They describe what the study did, which is not the same as a shelf life for a vial in your fridge.
- In vitro study, 2021: Degradation products (DPs) of GHRP-6, generated by heating in the dark at 60 °C with pH ranging from 3.0 to 8.0 and in presence of common buffers, were isolated by RP-HPLC and characterized by ESI-MS/MS. pmid-33272786
How GHRP-6 was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Clinical trial, humans, 2004: administration by intravenous route reported. GH response to i.v. bolus of GHRH+GHRP-6 (100 mcg, each) was measured in 12 male patients with type 2 diabetes (mean age: 53.9+/-1.59 years; BMI: 25.58+/-0.39 kg/m(2); mean HbA(1c): 8.7+/-0.42%), during a euglycemic (mean glucose: 4.92+/-0.08 mmol)… pmid-14693411
- Clinical trial, humans, 2000: administration by intravenous route reported. All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period. pmid-11030292
- Randomized controlled trial, humans, 1999: administration by intravenous, oral route reported. One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h). pmid-10583306
- Clinical trial, humans, 1999: administration by intravenous, oral route reported. After repeated intravenous (i.v.) boluses of growth hormone-releasing peptide-6 (GHRP-6) we found recently increases of growth hormone (GH), corticotropin (ACTH) and cortisol levels and of the amount of stage 2 sleep. pmid-10336729
- Controlled clinical trial, humans, 1995: administration by intravenous route reported. The subjects underwent 3 different tests on separate occasions, being challenged with GHRH (1 microgram/kg, iv), GHRP-6 (1 microgram/kg, iv), or GHRH plus GHRP-6. pmid-7593423
Questions people ask
- How many units is 400 mcg of GHRP-6?
- It depends entirely on how the vial was reconstituted. In a 5 mg vial with 2 mL of diluent it is 16 units on a U-100 syringe; with 1 mL it is 8. The chart above gives the rest.
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the GHRP-6 record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. A dose that appeared in a trial appeared under supervision, with monitoring, in people selected for that trial.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures